Baillie Gifford & Co
TXG icon

Baillie Gifford & Co’s 10x Genomics TXG Stock Holding History

Baillie Gifford & Co’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,378
Closed -$912K – 282
2024
Q3 		$912K Sell
40,378
-2,701,775
-99% -$55.9M ﹤0.01% 256
2024
Q2 		$53.3M Sell
2,742,153
-4,682,613
-63% -$123M 0.04% 138
2024
Q1 		$279M Sell
7,424,766
-495,210
-6% -$21.8M 0.22% 85
2023
Q4 		$443M Sell
7,919,976
-420,922
-5% -$18.3M 0.35% 65
2023
Q3 		$344M Sell
8,340,898
-163,349
-2% -$8.5M 0.31% 72
2023
Q2 		$475M Sell
8,504,247
-249,740
-3% -$13.5M 0.4% 58
2023
Q1 		$488M Buy
8,753,987
+151,752
+2% +$7.09M 0.44% 58
2022
Q4 		$313M Buy
8,602,235
+158,847
+2% +$5.19M 0.33% 71
2022
Q3 		$240M Buy
8,443,388
+64,417
+0.8% +$2.45M 0.25% 83
2022
Q2 		$379M Buy
8,378,971
+1,023,207
+14% +$53.1M 0.39% 69
2022
Q1 		$560M Buy
7,355,764
+477,387
+7% +$41.8M 0.39% 65
2021
Q4 		$1.02B Buy
6,878,377
+1,335,752
+24% +$205M 0.56% 50
2021
Q3 		$807M Buy
5,542,625
+511,629
+10% +$87.8M 0.42% 61
2021
Q2 		$985M Buy
5,030,996
+3,634,870
+260% +$658M 0.48% 52
2021
Q1 		$253M Buy
1,396,126
+621,106
+80% +$107M 0.14% 114
2020
Q4 		$110M Buy
775,020
+263,573
+52% +$38.2M 0.06% 128
2020
Q3 		$63.8M Buy
511,447
+507,150
+11,802% +$53.2M 0.04% 134
2020
Q2 		$384K Buy
4,297
+2,708
+170% +$211K ﹤0.01% 229
2020
Q1 		$99K Buy
+1,589
New +$124K ﹤0.01% 218

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Baillie Gifford & Co's TXG Position: Q4 2024 in Review

Baillie Gifford & Co sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 40,378 shares — an estimated $912K sold.

Baillie Gifford & Co first reported a position in TXG in Q1 2020 and held it in 19 quarters. The position peaked at $1.02B in Q4 2021. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

  • Baillie Gifford & Co reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 40,378 10x Genomics shares in Q4 2024, an estimated $912K.
  • Baillie Gifford & Co first reported a position in 10x Genomics in Q1 2020 and held it in 19 quarters.
  • Baillie Gifford & Co's 10x Genomics position peaked at $1.02B in Q4 2021.
  • 273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Baillie Gifford & Co's 13F filing for Q4 2024, filed 31 Jan 2025.